I agree that this site is using cookies. You can find further informations here.
X
Mascarenhas, John O.
422  results:
Online X
english X
Search for persons X
?
1

Management of isocitrate dehydrogenase 1/2 mutated acute my..:

Fruchtman, Harry ; Avigan, Zachary M. ; Waksal, Julian A...
Leukemia.  38 (2024)  5 - p. 927-935 , 2024
Link: https://doi.org/10.1038/..
 
?
2

Telomerase-targeted therapies in myeloid malignancies:

Waksal, Julian A. ; Bruedigam, Claudia ; Komrokji, Rami S...
Blood Advances.  7 (2023)  16 - p. 4302-4314 , 2023
Link: https://doi.org/10.1182/..
 
?
3

Treating accelerated and blast phase myeloproliferative neo..:

Ajufo, Helen O. ; Waksal, Julian A. ; Mascarenhas, John O..
Therapeutic Advances in Hematology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.1177/..
 
?
4

The clinical dilemma of JAK inhibitor failure in myelofibro..:

Mascarenhas, John O. ; Verstovsek, Srdan
Cancer.  128 (2022)  14 - p. 2717-2727 , 2022
Link: https://doi.org/10.1002/..
 
?
5

Determining the recommended dose of pacritinib: results fro..:

Gerds, Aaron T. ; Savona, Michael R. ; Scott, Bart L....
Blood Advances.  4 (2020)  22 - p. 5825-5835 , 2020
Link: https://doi.org/10.1182/..
 
?
6

Phase 2 study of ruxolitinib and decitabine in patients wit..:

Mascarenhas, John O. ; Rampal, Raajit K. ; Kosiorek, Heidi E....
Blood Advances.  4 (2020)  20 - p. 5246-5256 , 2020
Link: https://doi.org/10.1182/..
 
?
7

JAKs to STATs: A tantalizing therapeutic target in acute my..:

Venugopal, Sangeetha ; Bar-Natan, Michal ; Mascarenhas, John O.
Blood Reviews.  40 (2020)  - p. 100634 , 2020
Link: https://doi.org/10.1016/..
 
?
8

The Implications of Liver Biopsy Results in Patients with M..:

Tremblay, Douglas ; Putra, Juan ; Vogel, Alexander...
Case Reports in Hematology.  2019 (2019)  - p. 1-3 , 2019
Link: https://doi.org/10.1155/..
 
?
9

Metabolic Effects of JAK1/2 Inhibition in Patients with Mye..:

Sapre, Manali ; Tremblay, Douglas ; Wilck, Eric...
Scientific Reports.  9 (2019)  1 - p. , 2019
Link: https://doi.org/10.1038/..
 
?
10

Impact of High-Molecular-Risk Mutations on Transplantation ..:

Tamari, Roni ; Rapaport, Franck ; Zhang, Nan...
Biology of Blood and Marrow Transplantation.  25 (2019)  6 - p. 1142-1151 , 2019
Link: https://doi.org/10.1016/..
 
?
11

Ruxolitinib Therapy Followed by Reduced-Intensity Condition..:

Gupta, Vikas ; Kosiorek, Heidi E. ; Mead, Adam...
Biology of Blood and Marrow Transplantation.  25 (2019)  2 - p. 256-264 , 2019
Link: https://doi.org/10.1016/..
 
?
12

Leukemic Transformation of Myeloproliferative Neoplasms: Th..:

Li, Bing ; Mascarenhas, John O. ; Rampal, Raajit K.
Current Hematologic Malignancy Reports.  13 (2018)  6 - p. 588-595 , 2018
Link: https://doi.org/10.1007/..
 
?
13

Inhibition of interleukin-1 receptor-associated kinase 1 (I..:

Singer, Jack W. ; Fleischman, Angela ; Al-Fayoumi, Suliman...
Oncotarget.  9 (2018)  70 - p. 33416-33439 , 2018
Link: https://doi.org/10.18632..
 
?
14

Safety and efficacy of combined ruxolitinib and decitabine ..:

Rampal, Raajit K. ; Mascarenhas, John O. ; Kosiorek, Heidi E....
Blood Advances.  2 (2018)  24 - p. 3572-3580 , 2018
Link: https://doi.org/10.1182/..
 
?
15

"Irony" of managing refractory anemia with transfusional su..:

Lee, Sunyoung ; Salehi, Ilnaz ; Chary, Michael..
Transfusion and Apheresis Science.  55 (2016)  1 - p. 105-108 , 2016
Link: https://doi.org/10.1016/..
 
1-15